Disclosure of Share Capital and Voting Rights Outstanding as of September 30, 2016
(Pursuant to Article L.233-8 II of the French Commercial Code
and articles 221-1 and 223-16 of the General Regulations of the
Autorité des Marchés Financiers
)
Charenton-le-Pont, France (October 6, 2016 - 6.00 p.m.) - As of September 30, 2016, shares and voting rights outstanding of Essilor, the world leader in ophthalmic optics, broke down as follows:
September 30, 2016 | |
Shares outstanding | 218,137,805 |
Exercisable voting rights | 231,503,821 |
Total voting rights, based on all outstanding shares,
including shares stripped of their voting rights* | 234,359,884 |
(*) Shares held by the Company.
About Essilor
The world's leading ophthalmic optics company, Essilor designs, manufactures and markets a wide range of lenses to improve and protect eyesight. Its mission is to improve lives by improving sight. To support this mission, Essilor allocates more than €200 million to research and innovation every year, in a commitment to continuously bring new, more effective products to market. Its flagship brands are Varilux
®
, Crizal
®
, Transitions
®
, Eyezen
TM
, Xperio
®
, Foster Grant
®
, Bolon
TM
and Costa
®
. It also develops and markets equipment, instruments and services for eyecare professionals.
Essilor reported consolidated revenue of more than €6.7 billion in 2015 and employs 61,000 people worldwide. It markets its products in more than 100 countries and has 32 plants, 490 prescription laboratories and edging facilities, as well as 5 research and development centers around the world. For more information, please visit
www.essilor.com
.
The Essilor share trades on the Euronext Paris market and is included in the Euro Stoxx 50 and CAC 40 indices.
Codes and symbols: ISIN: FR0000121667; Reuters: ESSI.PA; Bloomberg: EI:FP.
------------------------
Investor Relations and Financial Communications
Phone: +33 (0)1 49 77 42 16